Nxera receives milestone payment from Centessa
Analysis based on 6 articles · First reported Sep 03, 2026 · Last updated Sep 03, 2026
The milestone payment provides a modest revenue boost to Nxera and validates its drug discovery platform, potentially supporting its stock price. For Eli Lilly, the progress of the OX2R agonist pipeline strengthens its position in neurological treatments, though the payment is immaterial to its overall financials.
On 3 September 2026, Nxera Pharma announced that KC Pharmaceuticals, a wholly-owned subsidiary of Eli Lilly and Company, achieved a late-stage development milestone in its selective orexin receptor 2 (OX2R) agonist portfolio. This milestone triggers a US$8.6 million payment to Nxera under their research collaboration. The payment will be recognized as revenue in Q3 of fiscal year 2026. Lilly completed its acquisition of Centessa on 24 June 2026, gaining ownership of the OX2R agonist pipeline. Nxera retains rights to future development and commercialization milestones and royalties. Christopher Cargill, President and CEO of Nxera, expressed satisfaction with the clinical progress and the portfolio's potential to address unmet needs in sleep-wake and neurological disorders.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard